Cora Therapeutics has reported positive clinical trial results for efficacy of Halo, an antioxidant supplement, in safeguarding DNA from radiation exposure during X-ray guided aortic aneurysm stenting procedures.

The results were unveiled by Dr Kieran Murphy, founder and CMO of the Toronto based start-up, during the Canadian Association of Interventional Radiologists (CAIR) annual meeting in Quebec City.

During the trial, physicians were administered the antioxidant complex as two capsules, one hour prior to exposure during the high-intensity image-guided procedures.

The reported results showed that the treated group experienced a 78% reduction in DNA breaks detected by p53 tests in their cell nucleus compared to the placebo group. The group given the antioxidant formulation exhibited a 54% decrease in mitochondrial DNA damage based on STAT 3 testing when compared to the placebo group.

Dr Murphy’s previous prospective, randomised human study (NCT01578395) reported statistical reduction in DNA breaks among patients undergoing nuclear bone scans. The research was published in the Journal of Vascular Interventional Radiology in 2016.

Halo has received clearance from Health Canada and the US Food and Drug Administration (FDA). In March 2023, Cora Therapeutics raised US $1 million in a second round of seed funding. The funds are expected to fuel the launch of Halo in North America.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData

The start-up is also looking to expand the indications for the formulation to include carcinogen induced DNA damage.

The current standard to reduce radiation exposure during X-ray guided procedures is the C-Arm scatter device shield system by Radiaction Medical Ltd. The shield system blocks radiation scatter at its source when used as an accessory to C-Arm X-ray devices.